Table 1.
Demographics and patient characteristics – safety analysis set (N = 16).
| HER2-mutant cervical cohort (N = 16) | |
|---|---|
| Median age (range), years | 55.0 (29–64) |
| Race, n (%) | |
| White | 13 (81.3) |
| Asian | 1 (6.3) |
| Black | 1 (6.3) |
| Other | 1 (6.3) |
| ECOG performance status, n (%) | |
| 0 | 6 (37.5) |
| 1 | 10 (62.5) |
| FIGO stage at diagnosisa, n (%) | |
| I | 7 (43.8) |
| II | 3 (18.8) |
| IIIB | 2 (12.5) |
| IV | 4 (25.0) |
| Histology, n (%) | |
| Endocervical adenocarcinoma | 10 (62.5) |
| Squamous cell carcinoma | 3 (18.8) |
| Adenocarcinoma | 2 (12.5) |
| Gastric type adenocarcinoma | 1 (6.3) |
| Median time from development of metastatic disease to enrollment (range), years | 1.2 (0.1–8.4) |
| Previous therapeutic interventionsb, n (%) | |
| Cisplatin | 5 (31.3)a |
| Carboplatin | 10 (62.5) |
| Paclitaxel | 15 (93.8) |
| Bevacizumab | 11 (68.8) |
| Topotecan | 2 (12.5) |
| Pembrolizumab | 2 (12.5) |
| Prior chemoradiation, n (%) | 6 (37.5) |
| Prior surgery, n (%) | 12 (75.0) |
ECOG: Eastern Cooperative Oncology Group; FIGO: International Federation of Gynecology and Obstetrics.
a
Five patients reported receiving cisplatin without concurrent radiation; of these, two had also previously received chemoradiation with cisplatin.
b
A complete list of previous systemic therapies is available in Supplementary Table S1.